These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 26531163)
1. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Dai L; Trillo-Tinoco J; Cao Y; Bonstaff K; Doyle L; Del Valle L; Whitby D; Parsons C; Reiss K; Zabaleta J; Qin Z Blood; 2015 Dec; 126(26):2821-31. PubMed ID: 26531163 [TBL] [Abstract][Full Text] [Related]
2. Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. Dai L; Lin Z; Qiao J; Chen Y; Flemington EK; Qin Z Oncogene; 2017 Aug; 36(35):5068-5074. PubMed ID: 28459467 [TBL] [Abstract][Full Text] [Related]
3. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma. Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996 [TBL] [Abstract][Full Text] [Related]
4. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Zillhardt M; Christensen JG; Lengyel E Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648 [TBL] [Abstract][Full Text] [Related]
5. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB. Gopalakrishnan R; Matta H; Chaudhary PM Clin Cancer Res; 2013 Sep; 19(18):5016-26. PubMed ID: 23881928 [TBL] [Abstract][Full Text] [Related]
6. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981 [TBL] [Abstract][Full Text] [Related]
7. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ mBio; 2018 May; 9(3):. PubMed ID: 29739902 [TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Capello D; Gaidano G; Gallicchio M; Gloghini A; Medico E; Vivenza D; Buonaiuto D; Fassone L; Avanzi GC; Saglio G; Prat M; Carbone A Leukemia; 2000 Feb; 14(2):285-91. PubMed ID: 10673746 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. Lam BQ; Dai L; Li L; Qiao J; Lin Z; Qin Z Oncotarget; 2017 Mar; 8(11):18373-18380. PubMed ID: 28407694 [TBL] [Abstract][Full Text] [Related]
10. PAX5 functions as a tumor suppressor by RB-E2F-mediated cell cycle arrest in Kaposi sarcoma-associated herpesvirus-infected primary effusion lymphoma. Goto H; Kariya R; Kudo E; Katano H; Okada S Neoplasia; 2024 Oct; 56():101035. PubMed ID: 39096792 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901 [TBL] [Abstract][Full Text] [Related]
12. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725 [TBL] [Abstract][Full Text] [Related]
13. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771 [TBL] [Abstract][Full Text] [Related]
15. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725 [TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization. Ueno M; Kariya R; Sittithumcharee G; Okada S Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222 [TBL] [Abstract][Full Text] [Related]
17. Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma. Chen J; Goyal N; Dai L; Lin Z; Del Valle L; Zabaleta J; Liu J; Post SR; Foroozesh M; Qin Z Blood; 2020 Nov; 136(19):2175-2187. PubMed ID: 32518949 [TBL] [Abstract][Full Text] [Related]
18. Diethyldithiocarbamate induces apoptosis in HHV-8-infected primary effusion lymphoma cells via inhibition of the NF-κB pathway. Matsuno T; Kariya R; Yano S; Morino-Koga S; Taura M; Suico MA; Shimauchi Y; Matsuyama S; Okamoto Y; Shuto T; Kai H; Okada S Int J Oncol; 2012 Apr; 40(4):1071-8. PubMed ID: 22200846 [TBL] [Abstract][Full Text] [Related]
19. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020 [TBL] [Abstract][Full Text] [Related]
20. Radiosensitization of brain metastasis by targeting c-MET. Yang H; Lee HW; Kim Y; Lee Y; Choi YS; Kim KH; Jin J; Lee J; Joo KM; Nam DH Lab Invest; 2013 Mar; 93(3):344-53. PubMed ID: 23381625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]